IBN (InvestorBrandNetwork) Announces EDGE Podcast Interview with Lexaria Bioscience Corp. CEO Chris Bunka
January 20 2022 - 8:00AM
via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted
financial news and publishing company for private and public
entities, today announces that Chris Bunka, Chairman and CEO of
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug
delivery platforms, recently appeared on the EDGE Podcast, a series
focused on providing the business owner's playbook about the inner
game of building a successful business and giving listeners the
edge to become smarter, healthier and richer.
The broadcast, hosted by Entrepreneur and Angel Investor Brandon
C. White, is available for on-demand listening on EDGE Podcast.
During the interview, Bunka provided an overview of Lexaria’s
business model and its efforts to improve the delivery of active
pharmaceutical ingredients, vitamins and minerals.
“Lexaria Bioscience is a tech company, and we provide really,
really interesting solutions to the pharmaceutical industry, as
well as nutraceuticals and even delivery of beneficial vitamins and
minerals in foods,” Bunka said. “Our technology is all about
enabling a much higher fraction and a much smoother delivery of the
beneficial substances in the foods you eat and in the drugs you
take and, quite frankly, getting them into your bloodstream. With a
lot of these compounds and drugs, the vast majority of what you eat
or swallow ends up in the toilet, and that’s no good. So, we can
fix that.”
Bunka next discussed the early days of his professional journey
and provided insight into some of the lessons he’s learned along
the way.
“I’ve been in business for 43 years. I started my first business
when I was 17. … I started to learn some of the aspects about
having employees and relying on other people. … Adding a layer of
management is a hurdle that I think most small businesses never
cross. … If you can navigate that, though, it gets to be a really
important threshold for future success,” Bunka said.
“I have done a lot of things over the years. In the early 2000s,
I was running money with a group of friends. We were investing in
companies as VCs. I heard a lot of stories, and we wrote a lot of
checks,” Bunka added. “A lot of small companies don’t do a good job
of understanding their competitive environment. A lot of them say,
‘I’m the best, I’m the fastest.’ … In the age of Google, I could be
on my laptop and have somebody pitching me on an idea, and I see
3,700 companies just like his. It makes it really hard, so
understanding your competitive environment is really, really
important, as well as understanding your products and
services.”
Throughout the interview, Bunka continued to provide insight
into his background and professional philosophies before turning
his attention to Lexaria’s ongoing efforts to leverage its
innovative drug delivery platform to improve the effectiveness of
orally delivered compounds.
Learn more by listening to the full interview on EDGE
Podcast.
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology,
DehydraTECH™, improves the way active pharmaceutical ingredients
(APIs) enter the bloodstream by promoting more effective oral
delivery. Since 2016, DehydraTECH has repeatedly demonstrated the
ability to increase bio-absorption with cannabinoids and nicotine
by up to 5-10x, reduce time of onset from 1-2 hours to minutes and
mask unwanted tastes; it is also being evaluated for orally
administered anti-viral drugs, non-steroidal anti-inflammatory
drugs (NSAIDs) and more. DehydraTECH has also evidenced an ability
to deliver some drugs more effectively across the blood brain
barrier. Lexaria operates a licensed in-house research laboratory
and holds a robust intellectual property portfolio with 21 patents
granted and over 50 patents pending worldwide. For more
information, visit the company’s website at
www.lexariabioscience.com.
About IBN
IBN (InvestorBrandNetwork) consists of financial brands
introduced to the investment public over the course of 15+ years.
With IBN, we have amassed a collective audience of millions of
social media followers. These distinctive investor brands aim to
fulfill the unique needs of a growing base of client-partners. IBN
will continue to expand our branded network of highly influential
properties, leveraging the knowledge and energy of specialized
teams of experts to serve our increasingly diversified list of
clients.
Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN
provides: (1) access to a network of wire solutions via
InvestorWire to reach all target markets, industries and
demographics in the most effective manner possible; (2) article and
editorial syndication to 5,000+ news outlets; (3) enhanced press
release solutions to ensure maximum impact; (4) full-scale
distribution to a growing social media audience; (5) a full array
of corporate communications solutions; and (6) a total news
coverage solution.
For more information, please visit
https://www.InvestorBrandNetwork.com.
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website, applicable to all content provided by
IBN wherever published or re-published:
http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
IBN (InvestorBrandNetwork)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lexaria Bioscience (NASDAQ:LEXX)
Historical Stock Chart
From Sep 2023 to Sep 2024